Inhibrx Biosciences Stock (NASDAQ:INBX)
Previous Close
$14.33
52W Range
$10.80 - $18.95
50D Avg
$15.75
200D Avg
$14.76
Market Cap
$200.20M
Avg Vol (3M)
$93.89K
Beta
2.88
Div Yield
$0.85 (6.15%)
INBX Company Profile
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
INBX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DICE | DICE Therapeutics, Inc. |
| VRDN | Viridian Therapeutics, Inc. |
| IKNA | Ikena Oncology, Inc. |
| MRUS | Merus N.V. |
| LRMR | Larimar Therapeutics, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| KRON | Kronos Bio, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| CELC | Celcuity Inc. |
| MACK | Merrimack Pharmaceuticals, Inc. |
| OPT | Opthea Limited |
| ELVN | Enliven Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |